A Decision Resources report sees a strong future for a Schering-Plough/Novartis asthma drug
Schering-Plough/Novartis' formoterol/mometasone could become the clinical gold standard for asthma by 2011 if the companies pursue both a metered dose inhaler (MDI) and dry powder inhaler (DPI) formulations of the drug. By doing so, they would beat out AstraZeneca's Symbicort (budesonide/formoterol fumarate dihydrate). That's the conclusion of a new report from market research firm Decision Resources. The Waltham, Mass., firm added that the current asthma market leader, GlaxoSmithKline's Advair, comes in both an MDI and DPI. The research company explained that pulmonologists value having a delivery device and formulation that can influence patient compliance.